PF-06840003 (EOS200271) (Synonyms: PF-06840003) |
| カタログ番号GC32879 |
PF-06840003 (EOS200271) (EOS200271) は、hIDO-1 および mIDO-1 に対して 0.41 μM、0.59 μM、および 1.5 μM の IC50 を有する高度に選択的な経口生物学的利用可能な IDO-1 阻害剤です。 、 それぞれ。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 198474-05-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor.
PF-06840003 reverses IDO-1-induced T-cell anergy in vitro[1].
PF-06840003 reduces intratumoral kynurenine levels in mice by >80% and inhibits tumor growth in multiple preclinical syngeneic models in mice, in combination with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours[1].
[1]. Tumang J, et al. PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr4863.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *